Many physicians are discouraged with the results of cancer thereapy. However, the opportunity is there for all physicianst o make an early diagnosis in all the gynecologic cancers except those in the tube and ovary. Stage for stage, little progress has been made in lowering mortality rates, but the overall mortality rate is decreasing because more patients are having their cancers diagnosed in early states of disease. This achievement is to the everlasting credit of the practicing doctors who have, by training and motivation, been successful in establishing early diagnosis as a protection for the women of the United States. Those women saved from the raves of cancer shall call their physicians blessed.
Cervical CA
•Pelvic exam
•CXR
•SMA-7
•Cystoscopy
•Proctoscopy
•IVP
•Not allowed: MRI, CT, ly
Staging Techniques:
Lymphangiography, surgical findings
PREINVASIVE LESIONS:
Cervix
•SIL
(W/U by colposcopy)
•Tx: CO2 Laser,
LEEP,Cryosurgery
asive Lesions:
Corpus
•Atypical Hyperplasia
(W/U by EMBx, D+C/hysts)
•Tx: Progestins,
hysterectomy,?GnRH-a
Many physicians are discouraged with the results of cancer thereapy. However, the opportunity is there for all physicianst o make an early diagnosis in all the gynecologic cancers except those in the tube and ovary. Stage for stage, little progress has been made in lowering mortality rates, but the overall mortality rate is decreasing because more patients are having their cancers diagnosed in early states of disease. This achievement is to the everlasting credit of the practicing doctors who have, by training and motivation, been successful in establishing early diagnosis as a protection for the women of the United States. Those women saved from the raves of cancer shall call their physicians blessed.
- Barber, 1980
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More